• HOME
  • Pipeline
  • Clinical Focus
  • Technology
  • Team
  • News
  • About
  • HOME
  • Pipeline
  • Clinical Focus
  • Technology
  • Team
  • News
  • About
  • canstockphoto6244971

    Febrile neutropenia is a common,
    life-threatening
    complication of chemotherapy

  • canstockphoto62820667

    Gut barrier Injury and Neutrophil
    depletion puts patients at risk for
    bacteremia and sepsis

  • canstockphoto7427952

    AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
    BACTERAEMIA BY STRENGTHENING
    INNATE GUT BARRIER DEFENSES

  • N1WT6iuIb

    eliminating the need for prophylactiC antibiotics

  • V1fz3suL-

    reducing risk of serious adverse events,
    antimicrobial resistance and
    microbiome dysbiosis

  • HOME
  • News
  • New employee

New employee

September 1, 2021

Akthelia has enlisted Steingrímur Stefánsson in the role of Senior Scientist. Steingrímur (Stenni) finished a Ph.D. Degree in molecular biochemistry from Virginia Commonwealth University in 1990 and has worked in senior roles for various biotech companies in the US since then. 

He has extensive experience in protein purification, protein modifications, protein-protein interactions, proteinases, their inhibitors. 

He also has a wide experience in cancer cell biology and assay development https://www.researchgate.net/profile/Steingrimur-Stefansson

AKTHELIA

  • Grandagarði 16, 101 Reykjavik
  • akthelia@akthelia.is
  • 610502-6440
  • Twitter
© 2023 AKTHELIA